Table 1.

Baseline characteristics.

No. (%)
Patients
 Screened39
 Enrolled33
 Evaluable for the primary endpoint24
Randomization
 Arm A18 (46)
 Arm B21 (54)
Number of patients receiving treatment
 CPC634 + conventional docetaxel26
 CPC63429
 Conventional docetaxel30
Age [years (IQR)]
 Median64 (16.5)
Gender
 Female12 (31%)
 Male27 (69%)
ECOG performance status
 010 (26%)
 129 (74%)
Previous lines of systemic treatment
 ≤233 (85%)
 >26 (15%)
Primary tumor
 Pancreatic carcinoma9 (23%)
 Esophageal carcinoma6 (15%)
 Carcinoma of unknown primary4 (10%)
 Cholangio carcinoma4 (10%)
 Urothelial carcinoma3 (8%)
 Other tumor types13 (33%)